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Aims Mice unable to locally regenerate corticosterone due to deficiency of 11b-hydroxysteroid dehydrogenase type 1
(11bHSD1) have enhanced angiogenesis during acute myocardial infarct healing. The present study investigates
the hypotheses that in these mice (i) inflammation and angiogenic signalling are promoted and (ii) longer-term remo-
delling and function are improved.
Methods
and results
Myocardial infarction (MI) was induced by coronary artery ligation in 11bHSD12/2 and wild-type (C57BL/6) mice.
Studies were terminated 2, 4, 7, and 28 days post-surgery. Increased vessel density (CD31 immunoreactivity) on the
infarct border was confirmed 7 days after MI in 11bHSD12/2 hearts (P, 0.05) and was accompanied by improved ejec-
tion fraction (ultrasound) compared with C57BL/6. During wound healing, recruitment of neutrophils (at 2 days after MI)
and macrophages (from 4 days after MI) and expression of monocyte-chemoattractant protein-1 was increased in
11bHSD12/2 compared with C57BL/6 hearts (P, 0.05). Recruitment of alternatively activated YM1-positive macro-
phages was particularly enhanced in the period preceding increased vessel density and was accompanied by increased
expression of pro-angiogenic IL-8. By 28 days post-MI, when the infarct scar had matured, higher vessel density was main-
tained in 11bHSD12/2 hearts and vessels were smooth-muscle coated. Infarct scars were thicker (P, 0.001) in
11bHSD12/2 compared with C57BL/6 hearts and ejection fraction was higher (P, 0.05).
Conclusion Increased vessel density in healing infarcts of mice deficient in 112/2HSD1 follows recruitment of pro-reparative
macrophages and increased pro-angiogenic signalling. Mature infarcts show less thinning and cardiac function is
improved relative to wild-type mice, suggesting that 11bHSD1 may be a novel therapeutic target after MI.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Angiogenesis † Inflammation † Alternatively activated macrophages † YM1 † IL-8
1. Introduction
Infarct expansion is an important determinant of long-term outcome
following myocardial infarction (MI). Therapeutic strategies aimed at
limiting infarct size, such as reperfusion, have led to reduction of
acute mortality post-MI. Despite this intervention, patients still
develop heart failure.1 Enhancing blood supply to the infarct border
through stimulation of angiogenesis, e.g. by injection of putative cell
progenitors or pro-angiogenic factors into the myocardium, reduces
infarct expansion and remodelling, and improves heart function in
experimental MI.1– 3 However, translation of this strategy to the
clinic has had limited success to date.4,5 An alternative approach is
to manipulate endogenous mechanisms involved in infarct healing so
that the associated angiogenic response is promoted.
Activation of corticosteroid receptors is regulated in target tissues
by pre-receptor metabolism of glucocorticoids by the isozymes of
11b-hydroxysteroid dehydrogenase (11bHSD).6 Following secretion
of active glucocorticoids (principally cortisol in humans and
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corticosterone in rodents) from the adrenal cortex under the control
of ACTH, these steroids are inactivated by 11bHSD2 (to cortisone
and 11-dehydrocorticosterone, respectively) in the kidney and a few
other tissues. These inert metabolites are then regenerated into
active glucocorticoid by 11bHSD1, which is expressed primarily in
glucocorticoid target tissues and has been implicated in the regulation
of cognitive, metabolic, and cardiovascular function.7,8 Importantly,
11bHSDs influence the intracellular concentrations of active gluco-
corticoids independently of any change in circulating plasma glucocor-
ticoids levels; changes in 11bHSD activity do alter metabolic clearance
rate of glucocorticoids, but the circulating level of cortisol (or corti-
costerone) is maintained by compensatory changes in ACTH and
adrenal secretion. In the cardiovascular system, 11bHSD1 is
expressed in the heart9,10 and in the vascular wall.11,12 In a previous
study, we showed that mice deficient in 11bHSD1 have enhanced
capacity for angiogenesis, and that vessel density is increased during
infarct healing after MI.13 However, the mechanism of increased neo-
vascularization in the hearts of 11bHSD12/2 mice is unknown, as are
the functional consequences for the heart. Inflammatory cells,
particularly monocyte/macrophages, are an important source of
pro-angiogenic cytokines, such as vascular endothelial growth factor
(VEGF) and interleukin-8 (IL-8).14 Depletion of monocytes/macro-
phages after experimental MI results in impaired angiogenesis on
the infarct border.15,16 In contrast, enhancement of monocyte recruit-
ment by overexpression of monocyte chemoattractant protein-1
(MCP-1),17 or direct injection of activated macrophages into the
heart,18 increases vessel density on the infarct border and improves
heart function.
Glucocorticoids are released into the systemic circulation acutely
after MI and appear to be initially cardioprotective, as blockade of
the glucocorticoid receptor (GR) increases infarct size.19,20
However, experimental and clinical studies have shown that pro-
longed exposure to high systemic levels of glucocorticoid, achieved
by administration of synthetic glucocorticoid, is detrimental following
MI,21,22 consistent with the ability of glucocorticoid to suppress
inflammatory processes essential for infarct healing.13,23,24 Deficiency
of 11bHSD1 exacerbates inflammation in murine models of arthritis
and sterile peritonitis,25 suggesting that locally regenerated glucocor-
ticoid also suppresses inflammation.
The present study was designed to investigate the hypothesis that
the lack of local glucocorticoid regeneration in 11bHSD12/2 mice
results in modification of the inflammatory response after MI resulting
in promotion of pro-angiogenic signalling in the healing myocardial
infarct. We also aimed to investigate whether the vessels formed
early after MI are retained after infarct healing is complete and impor-
tantly, whether there are beneficial consequences for cardiac remo-
delling and function in 11bHSD12/2 mice.
2. Methods
2.1 Animals
Ten- to 12-week-old male 11bHSD1 knock out (11bHSD12/2 con-
genic with C57BL/6) mice were bred from an in-house colony.26
Controls were commercial C57BL/6 mice (Harlan). The investigation
conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institute of Health (NIH Publi-
cation No 82-23 revised 1996) and was approved by the University
of Edinburgh ethics committee.
2.2 Coronary artery ligation
Mice (n ¼ 128) were anaesthetized (1 mg/kg medetomidine, 75 mg/kg
ketamine, and 600 mg/kg atropine) and received buprenorphine
(0.05 mg/kg) for analgesia. The trachea was intubated for mechanical ven-
tilation (120 strokes/min, 200 mL stroke volume, Hugo Sachs Elektronik
Minivent). The left thorax was opened at the fourth intercostal space
and the left main descending coronary artery was ligated with a 6.0
prolene suture. Sham animals did not have the ligature tied. Following
surgery mice received the reversal agent atipamezole (5 mg/kg) and
1.5 mL sterile saline intraperitoneally, and oxygen-enriched air until fully
recovered.
2.3 Corticosterone radioimmunoassay
Plasma corticosterone levels 24 h and every 7 days after surgery at the
diurnal nadir were measured by radioimmunoassay as described
previously.26
2.4 Ultrasound and tissue collection
At 2, 4, 7, or 28 days after surgery, heart function was assessed by ultra-
sound (Diasus 10–22 MHz probe, Dynamic Imaging, Livingstone, UK).
Left ventricular ejection fraction (%EF) was calculated as detailed in the
Supplementary Methods. The observer was blinded for ultrasound
measurements and all other analyses.
2.5 mg BrdU (Sigma) was administered i.p. 1 h prior to sacrifice to label
proliferating cells.27 The heart was removed and bisected down the longi-
tudinal axis through the infarct. One half was fixed in 10% neutral buffered
formalin for histology and immunohistochemistry. The other half was
frozen immediately and stored at 2808C.
2.5 Infarct size measurement
Infarct size at 24 h after MI was measured by triphenyltetrazolium chloride
(TTC, Sigma) staining as described previously.28
2.6 Histology and immunohistochemistry
Haematoxylin and eosin, Picrosirius Red, and Masson’s Trichrome stains
were used to identify neutrophils, collagen, and the infarct scar, respect-
ively. Immunohistochemistry was used to identify endothelial cells
(anti-CD31, BD Pharmingen), proliferating cells (anti-BrdU, Sigma),
macrophages (anti-mac 2, Cedarlane), alternatively activated macrophages
(anti-YM1, Stem cell Technologies), and activated myofibroblasts [anti-a
smooth muscle actin (SMA), Sigma]. Biotinylated secondary antibodies
(rabbit anti-rat, goat anti-mouse, and goat anti-rabbit, 1:200, Vector)
were subsequently added prior to extravidin peroxidase (Sigma). Detec-
tion of peroxidase activity was with the 3,3-diaminobenzidine kit
(Vector). Sections were counterstained with haematoxylin, dehydrated,
and mounted in DPX resin (Fluka). See Supplementary Methods for
further details.
For quantification, sections were tiled at ×25 or ×100 magnification
(Image Pro6.2, Stereologer Analyser 6 MediaCybernetics). Neutrophils
(identified morphologically) and counted in 10 randomly assigned
40 mm2 areas of left ventricle (LV); CD31 and aSMA positive vessels
(less than 200 mm in diameter) were counted in 10 randomly assigned
400 mm2 areas of LV, and an average per LV calculated.29 BrdU positive
cells were counted per mm2. Macrophage (Mac 2 and YM1) staining
was calculated based on percentage staining of the infarct border. The
area of collagen deposition (Picrosirius Red) and scar area (Masson’s
Trichrome) were quantified as a percentage of the total LV. Scar thickness
was calculated from the thickness of three points on the scar and aver-
aged. Epicardial infarct length was calculated as epicardial infarct length/
epicardial length × 100.28
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2.7 RNA isolation and quantitative real-time
reverse-transcription polymerase chain
reaction
One microgram RNA extracted from the frozen half heart using Trizol (Invi-
trogen, Paisley, UK) was reverse transcribed to cDNA (Applied Biosystems
high capacity cDNA reverse transcription kit). TAQmanw gene expression
assays were used to detect interleukin 6 (IL-6 Mm99999064_m1), monocyte
chemotactic protein 1 (MCP-1 Mm00441242_m1), and KC (mouse homol-
ogue of interleukin 8 which will be referred to as IL-8, Mm00433859_m1).
mRNA expression levels were normalized for GAPDH expression and pre-
sented as fold increases over sham control analysed in parallel.
2.8 Statistical analysis
All values are expressed as mean+ SEM. Comparisons of day 2–7 data
are by two-way ANOVA with Bonferroni post hoc tests, with the excep-
tion of qRT–PCR data which are by Kruskal–Wallis testing. Two-tailed
unpaired Student’s t-tests were used to compare infarct size and 28 day
data. P-values , 0.05 denote statistical significance.
3. Results
3.1 Survival, infarct size, and plasma
corticosterone after MI
Survival rate was 76% (63/83 total) in C57BL/6 and 78% (35/45 total)
in 11bHSD12/2 mice, and in both groups, death was due to acute
heart failure or rupture during early infarct healing. TTC staining
showed that the extent of LV damage 24 h after MI was comparable
in C57Bl6 (35.1+ 1.0% of LV, n ¼ 6) and 11bHSD12/2 (37.8+2.4%,
n ¼ 6) mice. At this time, the plasma corticosterone concentration
was 10-fold higher than basal levels.26 Plasma corticosterone declined
by day 7 to approximately 75 nmol/L (Supplementary material online,
Figure S1) in both C57BL/6 and 11bHSD12/2 mice.
3.2 Inflammatory cell recruitment during
infarct healing
At 2 days after MI, there was significant neutrophil recruitment to the
LV relative to sham operation (P, 0.01, Figure 1). In 11bHSD12/2
mice, the number of neutrophils in the LV at this time was significantly
enhanced compared with C57BL/6 (P, 0.01). Thereafter, neutrophil
content decreased to similar levels as the sham-operated controls in
both groups (Figure 1). Early expression of the neutrophil
chemo-attractants IL-6 and IL-8 did not increase significantly in
11bHSD12/2 compared with C57BL/6 mice (day 2 IL-6 expression
1.14+ 0.01 relative to sham in C57BL/6 and 1.22+ 0.02 relative to
sham in 11bHSD12/2; day 2 IL-8 expression 1.14+0.01 relative to
sham in C57BL/6 and 1.17+0.02 relative to sham in 11bHSD12/2,
n ¼ 6 per group).
Mac 2 immunoreactive macrophages were identified predominantly
in the infarct and border zone, becoming evident from 2 days after MI
(Figure 2D and E). The extent of mac 2 immunoreactivity was further
increased at 4 and 7 days post-MI relative to sham operation (P,
0.001, Figure 2A and E). In hearts from 11bHSD12/2 mice, macro-
phage accumulation tended to be increased relative to controls and
this was significant by 7 days after MI (P, 0.01, Figure 2A). Flow cyto-
metric analysis of LV homogenates also demonstrated increased
content of CD11b+ve monocyte/macrophages in 11bHSD12/2
hearts at this time (data not shown). Expression of the macrophage
chemoattractant MCP-1 mRNA was also greater in the LV of
11bHSD12/2 compared with control mice 7 days after MI (P,
0.01, Figure 2B). Specific immunostaining for the subset of
pro-angiogenic and reparative ‘alternatively-activated’ macrophages,
identified by YM1, revealed increased accumulation at 4 and 7 days
post-MI relative to sham-operated mice, in which staining was negli-
gible (Figure 2C and F ). In 11bHSD12/2 mice, accumulation of
YM1-positive macrophages was significantly greater than in C57BL/6
controls (P, 0.05) by 4 days after MI (Figure 2C). Detection of acti-
vated myofibroblasts using a-smooth muscle actin (aSMA) showed
significant accumulation of immunopositive cells from 4 days after
MI (Supplementary material online, Figure S2), consistent with scar
maturation. However, there was no significant influence of genotype
on aSMA immunoreactivity at either time point.
3.3 Post-infarct neovascularization and
pro-angiogenic signalling
The density of small (,200 mm in diameter) CD31-positive blood
vessels increased after MI, particularly on the infarct border
(Figure 3A and C). Consistent with increased vessel formation, cell
proliferation, identified by BrdU incorporation, was also increased
at the same site (Figure 3B and C). By 7 days after MI, both vessel
density (P, 0.05, Figure 3A) and cell proliferation (P, 0.01,
Figure 3B and C ) were significantly higher in 11bHSD12/2 than in
C57BL/6 control hearts. This was accompanied by increased
abundance of the pro-angiogenic signalling molecule IL-8 mRNA in
the LV of 11bHSD12/2 hearts (P, 0.01, Figure 3D). Expression of
Figure 1 Neutrophil infiltration during infarct healing. (A and B)
Neutrophils were identified in the left ventricular myocardium
(LV) by their distinctive multi-lobed nuclei in haematoxylin and
eosin-stained sections, counted and expressed as number per
10 mm2. (B) Tiled heart 2 days post-infarction showing neutrophil
invading infarct border. IA, infarct area; RV, right ventricle. Arrows
point to neutrophils. n ¼ 8, C57BL/6 sham; n ¼ 12, C57BL/6 MI;
n ¼ 4, 11bHSD12/2 sham; n ¼ 6, 11bHSD12/2 MI. ##P, 0.01,
###P, 0.001 (versus matched sham), **P, 0.01 (C57BL/6 versus
11bHSD12/2). Scale bar, 10 mm.
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VEGFa mRNA was not increased after MI in either C57BL/6 or
11bHSD12/2 hearts at this time (Figure 3D) or earlier during infarct
healing (e.g. VEGF expression was 1.02+0.09 and 1.00+ 0.05 com-
pared with sham in C57BL/6 at 2 and 4 days after MI; 1.02+ 0.03 and
0.98+ 0.02 compared with sham in 11bHSD12/2 hearts at 2 and
4 days after MI, n ¼ 6 per group).
3.4 Cardiac function during early infarct
healing
There were no differences in basal cardiac function between
un-operated 11bHSD12/2 and C57BL/6 mice (Supplementary
material online, Table S1). After sham operation, ejection fraction
(EF) was consistently above 60% in both C57BL/6 and
11bHSD12/2 mice, and was not different between these two
groups (see Supplementary material online, Table S1). After MI, EF
was significantly reduced in all mice, compared with sham operation
(e.g. at 7 days after surgery EF was 32+4% in MI compared with
64+ 5% in sham-operated C57BL/6 mice, P, 0.01). EF was similarly
depressed in both C57BL/6 and 11bHSD12/2 at 2 and 4 days after MI
(Figure 4). However, by 7 days after MI, EF was significantly improved
in 11bHSD12/2 compared with control mice (P, 0.05, Figure 4).
3.5 Post-infarct healing characterization
Investigation of cardiac function at 28 days after MI, when infarct
healing was largely complete, revealed that the improvement in
function in 11bHSD12/2 mice apparent at 7 days after MI was
Figure 2 Macrophage accumulation during infarct healing. (A, D, E) mac 2 immunohistochemistry was used to detect macrophage infiltration and
was quantified as percent staining of the infarct border (IB). (B) Monocyte chemoattractant protein-1 (MCP-1) mRNA levels in heart tissue normalized
to GAPDH housekeeping gene. (C, F ) YM1-positive staining in heart tissue showing alternatively activated macrophages and quantified as percent
staining of the infarct border. YM1 staining was absent from the hearts of mice that underwent sham operation (C). n ¼ 8, C57BL/6 sham;
n ¼ 12, C57BL/6 MI; n ¼ 4, 11bHSD12/2 sham; n ¼ 6, 11bHSD12/2 MI; for RT–PCR n ¼ 6 per group. ##P, 0.01, ###P, 0.001 (sham versus
MI). *P, 0.05, **P, 0.01, ***P, 0.001 (C57BL/6 versus 11bHSD12/2). Scale bar, 10 mm.
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retained (P, 0.01, Figure 4). Dysfunction post-MI was not associated
with chamber dilatation at this point, as LV end-diastolic area
remained consistent throughout the post-operative period in all
mice (data not shown).
In hearts collected 28 days after MI, the density of small CD31-
positive vessels also remained higher in 11bHSD12/2 relative to
C57BL/6 hearts (P, 0.05, Figure 5A). Furthermore, the number of
aSMA immunopositive vessels was also increased in 11bHSD12/2
hearts (P, 0.001, Figure 5B), suggesting that some of the new
vessels had matured and become pericyte coated (Figure 5C). The
extent of fibrosis and scar area, evaluated by Picrosirius Red and
Masson’s Trichrome staining, were comparable between control
and 11bHSD12/2 mice 28 days post-MI (Figure 6A and B).
However, 11bHSD12/2 mice had significantly thicker infarcts than
C57BL/6 mice (P, 0.001, Figure 6C and E) and the scars had a ten-
dency to be shorter (Figure 6D).
4. Discussion
We have previously shown that deficiency of 11bHSD1 is associated
with increased vessel formation in experimental models of angiogen-
esis in vitro and in vivo, including in the healing myocardium of mice that
have undergone MI.13 In the current study, we aimed to extend these
observations by investigating whether modification of inflammation
during infarct healing might provide a stimulus for increased vascular-
ization in 11bHSD12/2 mice. We additionally aimed to investigate
whether these acute vascular changes translated into sustained func-
tional improvement. The data demonstrate that increased neovascu-
larization during infarct healing in 11bHSD12/2 mice follows
increased accumulation of neutrophils and of alternatively activated
macrophages, and occurs in parallel with increased expression of
the pro-angiogenic chemokine, IL-8. Furthermore, enhanced blood
Figure 3 Vessel density and cell proliferation during infarct healing. (A) CD31-positive vessels ,200 mm in diameter in the LV, expressed per
400 mm2. (B) Nuclei positive for BrdU incorporation in the LV, expressed per mm2. (C) Representative sections of infarct border at 7 days after infarc-
tion, arrows point to CD31-positive vessels. (D) Interleukin 8 (IL-8) and vascular endothelial growth factor a (VEGFa) mRNA expression levels in
heart tissue normalized to GAPDH housekeeping gene at 7 days after MI. n ¼ 8, C57BL/6 sham; n ¼ 12, C57BL/6 MI; n ¼ 4, 11bHSD12/2 sham;
n ¼ 6, 11bHSD12/2 MI; for RT–PCR n ¼ 6 per group. #P, 0.05, ###P, 0.001 (sham versus MI). *P, 0.05, **P, 0.01 (C57BL/6 versus
11bHSD12/2). Scale bar, 10 mm.
Figure 4 Heart function during and after infarct healing. Ejection
fraction was calculated from the LV end-diastolic area (LVEDA)
and LV end-systolic area (LVESA) and expressed as a percentage.
Data are presented as mean+ SEM, lighter columns C57BL/6,
darker columns 11bHSD12/2. (for C57BL/6, n ¼ 12 MI during
early healing at 2, 4, and 7 days after MI, n ¼ 10 for MI at day 28;
for 11bHSD12/2 n ¼ 6 MI day 2, 4, and 7, and n ¼ 9 for MI day
28). *P, 0.05, **P, 0.01 C57BL/6 versus 11bHSD12/2.
11bHSD1 and myocardial infarct healing 163
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vessel density is retained at 28 days post-MI in 11bHSD12/2 mice, by
which time vessels on the infarct border have matured, scar thinning is
reduced, and cardiac function is improved.
Neovascularization on the infarct border typically begins during the
reparative phase of healing.30,31 In the present study, the number of
CD31-positive blood vessels in the LV increases during this period
between 4 and 7 days after MI. Increased incorporation of BrdU
into cells on the infarct border over the same period is consistent
with the endothelial cell proliferation that is known to contribute
to new blood vessel formation.27 In mice deficient in 11bHSD1,
vessel density is higher during infarct healing, in agreement with our
previous observations,13 and cellular proliferation is also significantly
increased. Glucocorticoids are known to suppress endothelial cell
proliferation.32 Promotion of angiogenesis in the hearts of
11bHSD12/2 mice is consistent with lifting of this suppression in
mice unable to regenerate glucocorticoid, permitting enhanced pro-
liferation. The primary stimulus for neovascularization after MI is
from pro-angiogenic cytokines and chemokines released by
neighbouring cells in the infarct. IL-8 is secreted by macrophages
and endothelial cells in the healing infarcts, acts as a chemoattractant
for bone marrow-derived endothelial progenitor cells, and can
promote endothelial cell proliferation.33,34 In the present study, we
find that expression of IL-8 is significantly increased in the LV of
11bHSD12/2 mice, suggesting that mechanisms other than direct
regulation of cellular proliferation may contribute to increased neo-
vascularization in the absence of 11bHSD1 activity.
Monocyte/macrophages have a key role in regulation of
injury-associated angiogenesis.15,35 When macrophage accumulation in
the infarct is prevented, following depletion by liposome-encapsulated
clodronate, angiogenesis is abolished.15,16,36 Glucocorticoids downre-
gulate inflammatory cytokines, upregulate anti-inflammatory cytokines,
and modulate phagocytosis by macrophages.23,24,37 Macrophages
express 11bHSD1 and its expression is upregulated after activation,37,38
which may serve to curtail the inflammatory response in the healing
myocardial infarct. In support of this hypothesis, investigation of
hearts from 11bHSD12/2 mice after MI reveals that accumulation of
both neutrophils and macrophages is magnified in comparison to
hearts from C57BL/6 mice. Infarct size is a key stimulus for inflamma-
tory cell infiltration after MI,39,40 but deficiency of 11bHSD1 has no
effect on ischaemia-associated damage to the myocardium. Systemic
corticosterone, released from the adrenal gland in response to surgical
stress and MI, is another potential modulator of myocardial inflam-
mation. However, the 11bHSD12/2 mice have comparable basal sys-
temic corticosterone and response to MI as the wild-type mice; this
is consistent with control of circulating corticosterone by ACTH
being independent of peripheral 11bHSD activity, and with previous
reports of normal plasma corticosterone in 11bHSD12/2 mice on a
C57BL/6 background.41 If anything, plasma corticosterone levels
tended to be a little higher in 11bHSD12/2 mice, which also occurs
with 11bHSD1 deletion on a mixed genetic background42 and would
be anticipated to oppose the beneficial effects on outcome from MI
observed here. This emphasizes that local intracellular changes in gluco-
corticoid generation in the heart, or elsewhere, are more likely to be
regulating the inflammatory response post-MI.
Neutrophils are attracted to the heart very soon after infarction
and contribute to cell removal during the early inflammatory phase
of infarct healing as well as releasing cytokines e.g. IL-4 that regulate
the later reparative phase. Enhanced neutrophil accumulation in
11bHSD1 hearts may therefore impact on both of these phases of
infarct repair. The mechanism of increased neutrophil accumulation
in 11bHSD12/2 hearts is not clear. Recruitment is regulated by
IL-6 and IL-8,40 but there is no difference in expression of these cyto-
kines in 11bHSD12/2 compared with C57BL/6 hearts, at least at
2-day post-MI mice. This may indicate that early cytokine expression
is not a mechanism for enhanced neutrophil recruitment in
11bHSD12/2 mice. However, we cannot rule out the possibility
that acute differences in expression may have been masked by the
changes in cytokine expression that are associated with acute surgical
trauma, as previously described.43 Mice deficient in glucocorticoids
following adrenalectomy have increased expression of the adhesion
molecules that have a role in tethering neutrophils to the endothelium
prior to translocation into inflamed tissue.44 Reduced availability of
glucocorticoids in the 11bHSD12/2 mice may therefore provide a
similar stimulus for enhanced retention of neutrophils post-MI.
Once in the infarct, neutrophils undergo apoptosis and are
removed by the phagocytic activity of macrophages.45 An alternative
explanation for our findings is that neutrophils undergo less or
Figure 5 Blood vessel density and pericyte coverage 28 days after
MI. (A) CD31 and (B) a smooth muscle actin (aSMA smooth muscle
cells) positive vessels ,200 mm in diameter counted in sequential
sections from the LV, expressed per 400 mm2. (C) Representative
sections showing typical double immuno-staining for CD31
(brown) and aSMA (blue) on the infarct border of C57BL/6
(C57BL6) and 11bHSD12/2 (11HSD12/2) hearts . Filled arrows
point to pericyte, smooth muscle coated vessels, open arrows
point to pericyte poor, smooth muscle negative vessels. n ¼ 10,
C57BL/6 MI; n ¼ 9, 11bHSD12/2 MI. *P, 0.05, ***P, 0.001.
Scale bar, 10 mm.
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delayed apoptosis in 11bHSD12/2 mice. There is, however, no evi-
dence for delayed neutrophil removal in 11bHSD12/2 compared
with C57Bl/6 mice. Furthermore, this mechanism appears unlikely as
glucocorticoids tend to inhibit neutrophil apoptosis46 and reduced
local glucocorticoid availability would therefore be expected to
enhance, rather than reduce neutrophil apoptosis.
Monocytes are attracted to the infarct by monocyte chemotactic
protein-1 (MCP-1), also secreted by macrophages.17,47 In the
present study, expression of MCP-1 mRNA is increased in
11bHSD12/2 hearts in parallel with increased macrophage accumu-
lation. Nahrendorf et al.15 have suggested that alternatively activated,
pro-angiogenic monocytes present during the reparative phase of
healing play a vital role in infarct healing. Unlike classically activated
macrophages that secrete pro-inflammatory mediators and display
phagocytic behaviour, alternatively activated macrophages secrete
anti-inflammatory and angiogenic cytokines such as TGFb, IL-4, and
IL-8 and can be identified by secretion of the chitinase-like molecule
YM1.48,49 Data presented here shows for the first time that YM1-posi-
tive macrophages are indeed present in healing myocardial infarcts.
Furthermore, immunostaining revealed the presence of a greater pro-
portion of YM1-positive, alternatively activated macrophages in the
infarct border of 11bHSD12/2 mice during the reparative phase of
healing. These macrophages are the likely source of IL-8, expression
of which is increased at the time of angiogenesis in the
11bHSD12/2 mice. Further studies are required to elucidate the
mechanism for preferential assumption of the pro-reparative pheno-
type in 11bHSD12/2 mice and to investigate its importance in deter-
mining the increased vessel density in these mice.
It is clear from many studies that enhancement of angiogenesis on
the infarct border post-MI improves heart function.1 –3,28,34,50 In the
present study, we show that cardiac function in 11bHSD12/2 mice
is similar to that in C57BL/6 mice early after infarction, but by 7
days post-MI, at the time when increased vessel density is clear, ejec-
tion fraction is also enhanced. Increased vessel density early after
infarction therefore appears to be of benefit, potentially by increasing
blood supply to cardiomyocytes on the infarct border, but if this is to
remain it is important that the early capillaries mature so that blood
supply is maintained. As the scar heals, the early vessels are either
pruned or they mature by gaining pericyte coverage.30,31 In hearts
of 11bHSD12/2 mice, we show that increased vessel density is
retained at 28 days post-MI, by which time many of the vessels
have become smooth muscle coated. Correspondingly, ejection frac-
tion also remained higher in 11bHSD12/2 compared with control
mice at this time. By 28 days after MI, the infarcted myocardium
was replaced by a collagen rich scar. Assessment of the scar structure
revealed that although the overall scar area was similar, scars from
11bHSD12/2 mice were thicker and tended to be shorter than
those from control mice. Failure to show a significant reduction in
scar length is a limitation of the study, likely because of insufficient
mice to account for the variability in this parameter. It is possible
Figure 6 Fibrosis and scar formation 28 days after MI. (A) Collagen deposition measured from Picrosirius Red stained sections and expressed as
percent staining of the LV in C57BL/6 (C57BL6, light columns) and 11bHSD12/2 (11HSD12/2, dark columns) hearts . (B–E) Scar dimensions and
infarct lengths were assessed from Masson’s Trichrome stained sections (B). (C) Scar area expressed as the percentage of the LV. (D) Scar thickness
was averaged from three points taken across the scar. (E) Epicardial infarct length expressed as a percentage of the epicardial LV length. n ¼ 10,
C57BL/6 MI; n ¼ 9, 11bHSD12/2 MI for Picrosirius Red and Masson’s Trichrome staining. ***P, 0.001 (C57BL/6 versus 11bHSD12/2). Scale
bar, 10 mm.
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that enhancement of blood supply to the infarct border resulted in
salvage of cardiomyocytes, as has previously been reported,50 redu-
cing infarct expansion and contributing to increased cardiac contrac-
tility. The chitinase-like activity of YM1, present to a greater extent in
11bHSD12/2 hearts, can aid in matrix reorganization and wound
healing,48,51 and this may also have contributed to the reduction in
infarct thinning observed in these mice. Macrophages have an impor-
tant role in scar formation by enhancing fibrosis.16 Macrophage
secretion of transforming growth factor-b can activate myofibroblasts
subsequently leading to collagen production.52,53 However, the data
presented here indicate that despite greater macrophage accumu-
lation in 11bHSD12/2 mice, myofibroblast activation and fibrosis
were not increased relative to controls.
In summary, the present results support the hypothesis that inflam-
matory cell recruitment after MI is modified in mice deficient in
11bHSD1 and that this provides an enhanced stimulus for angiogen-
esis in the healing infarcts of these mice. Furthermore, increased
vessel density is associated with reduction of infarct thinning and sus-
tained functional improvement after MI. Glucocorticoids can activate
both GR and mineralocorticoid receptor (MR). Blockade of MR soon
after MI resulted in improvement in cardiac function in the EPHESUS
clinical trial 54 and in an experimental model of MI.36 It may therefore
be prevention of MR activation by locally generated corticosterone
that accounts for the present observations in 11bHSD12/2 mice,
and this requires confirmation in further studies. While the MR antag-
onist Eplerenone is currently being used clinically post-MI, it can lead
to hyperkalaemia.54 Inhibitors of 11bHSD1 are in phase II trials for
treatment of diabetes and other data suggest that they will prove ben-
eficial in obesity, and atherosclerosis.55 The present data suggest that
they may also provide an alternative approach for regulation of corti-
costeroid activity after MI.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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